Merck & Co., Inc. vs Abbvie Inc.
MRK vs ABBV — side-by-side comparison from reported financials. MRK leads 4, ABBV leads 6 of 10 comparable metrics.
Merck & Co., Inc.
MRK · Healthcare
$146.33+2.77%Mixed
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | MRK | ABBV |
|---|---|---|
| Price | $146.33 | $276.43 |
| Market cap | $361B | $488B |
| Revenue (TTM) | $66.6B | $64.4B |
| Revenue growth | +3.1% | +1.8% |
| Net margin | 4.8% | 9.8% |
| Free cash flow | $16.1B | $18.2B |
| Net cash (debt) | ($34.8B) | ($56.2B) |
| 1-year price return | +67.2% | +19.8% |
| P/E | 113.2 | 77.4 |
| P/E vs own history (cheap-side %) | 7% | 23% |
| Dividend yield | 2.31% | 2.45% |
| Return on equity | 7% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 9 of 11 | 9 of 11 |
| Employees | 75,000 | 57,000 |
Full résumé-style profiles: MRK CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.